Home Tags HER2-positive

Tag: HER2-positive

Harnessing the Power of Three: Advancing Antibody-Drug Conjugates from Laboratory to...

Antibody-drug conjugates or ADCs are creating much excitement among life science professionals, medical/clinical research scientists and pharmaceutical specialists. At the same time, oncologists and hematologists are eager to welcome new treatment options in the ongoing war against cancer. This article reviews some of the advances made in the development of ADCs.

The Next Advancements in Cancer Drug Development: Antibody-Drug Conjugates

The annual meeting of the American Society of Clinical Oncology (ASCO) conference held June 1-5, 2012 in Chicago, IL offered a wealth of new...

Monoclonal Antibodies (mAbs), the “Magic Bullets” of Cancer Care, Are Now...

Monoclonal Antibodies (mAbs), once touted as the "magic bullets" of cancer care, are now fulfilling that promise and more advances are on the way,...

Antibody-drug Conjugate for MBC Highlights Importance of Personalised Approach to Cancer...

Results of the first randomized phase II study, known as TDM4450g, in patients with previously untreated HER2-positive metastatic breast cancer (mBC) were presented today at...

Investigational Antibody-Drug Conjugate, Shows Encouraging Results in Women With Highly Advanced...

Results of a Phase II study of trastuzumab (Herceptin®, Genentech) in combination with DM1 (T-DM1), an investigational HER2 antibody-drug conjugate being developed by Genentech,...

X